Arcus, a decentralized exchange on Robinhood Chain, suffered a $2.2 million USDG payout to an exploiter due to an integer underflow bug that inflated account balances. An automated bridge rate limit prevented an additional $3 million in withdrawals, limiting the damage. Arcus covered the loss from its treasury, paused withdrawals promptly, and is negotiating with the exploiter for token returns. The incident highlights risks in internal accounting logic rather than smart-contract flaws and underscores the value of automated safeguards.
Arcus's $2.2 million USDG payout after an integer underflow exploit provides context for readers following decentralized finance incidents. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 13, 2026 17:21 WIB: out of 50 priced major cryptocurrencies, 12 rose and 37 fell today. Notable movers include BAL (Balancer) at Rp16.297 with a +11.14% change and a typical hold time of 85 days, ONE (Harmony) at Rp27 with a -8.41% change and a 40% sell / 60% buy order activity, and EOS (EOS.IO) at Rp12.649 with an +8.13% change and a typical hold time of 87 days.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
